The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Open accessAbstract
Background: Stopping antidepressants is often difficult due to withdrawal. Taperingstrips were developed to facilitate antidepressant discontinuation according to the recently described Horowitz-Taylor method, allowing for personalised titration of discontinuation to the intensity of withdrawal. A taperingstrip consists of antidepressant or other medication, packaged in a 28-day roll of small daily pouches, each with the same or slightly lower dose than the one before it. We previously reported that the short-term success rate of antidepressant taperingstrips was 71%. Here, we examine longer-term outcome after 1–5 years. Methods: Patients whose doctor had ordered taperingstrips between January 2015 and December 2019 were sent a questionnaire for participation in anonymised research in January 2020. Of 1012, 483 participated, of whom 408 (85%) had attempted antidepressant tapering. Results: Of the 408 patients included, 192 (47%) had used strips for tapering venlafaxine, 142 (35%) for paroxetine and 74 (18%) for other antidepressants. Median length of antidepressant use was 4 years, and most (61%) had tried to come off without taperingstrips at least once. After 1–5 years, 270 patients (66%) remained off antidepressants after tapering their antidepressant, 6 (2%) had successfully reduced their medication, 87 (21%) had restarted due to (self-reported) relapse, 35 had restarted for another indication (9%), and 10 (3%) reported another outcome. People with more severe experience of withdrawal prior to tapering, and people who had been on antidepressants for a shorter period of time, were more likely to remain off medication after 1–5 years. Conclusion: The previously reported 71% short-term success rate of taperingstrips in the most severely affected group, was matched by a 68% rate after 1–5 years. The evidence-based approach of personal tapering to counter withdrawal, as used for drugs causing withdrawal, for example, benzodiazepines, may represent a simple solution for an important antidepressant-related public health problem, without extra costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of participants who had tapered successfully using tapering strips, 72% was still without antidepressant 1–5 years later (follow-up data study 2)21.”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [21]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“71% of the 895 participants (97% of whom had experienced some withdrawal previously) discontinued their medication over a median of 56 days, with 68% still off their antidepressant a er one to five years (Groot 2018Groot 2020).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Groot 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that they were by far the most common antidepressants that tapering strips were requested for in this and previous surveys23,26,27 suggests, given over-representation in the study group relative to overall prescription rates, that use of these medications is associated with greater risk of withdrawal, as widely recognised”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, preliminary data from non-randomised trials suggest that hyperbolic tapering through tapering strips may reduce the incidence of withdrawal symptoms.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The questionnaire was the same as the one that was used in the first published study.21”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [21]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Critical Slowing Down as a Personalized Early Warning Signal for Depression
Wichers, M., Groot, P. C., & Psychosystems, E. G. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441458 · Cited by 399
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Read, J., & Williams, J. (2018) · Current Drug Safety · doi:10.2174/1574886313666180605095130 · Cited by 175
Kaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0910 · Cited by 135
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Marsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30331-1 · Cited by 106
Weller, I. V. D., Ashby, D., Brook, R., Mga., C., Chick, J., Drummond, C., Ebmeier, K. P., Gunnell, D., Hawking, H., Mukaetova‐Ladinska, E. B., et al. (2005) · Cited by 74
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Research works printed but not linked: 1
- Groot PC., 2017, Development and Rationale of Taperingstrips. Report for Taperingstrip Preparatory Meeting Zorginstituut Nederland, 29-3-2017
Cited by
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211067656 · Cited by 52
Metadata
- Authors
- Groot, P. C., & van Os, J.
- Affiliations
- King's College London (GB)
- User Research Centre Netherlands, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320954609-2045125320954609
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7476339
- OpenAlex
- W3082889307
- Cited by
- 35
- References
- 19
- Citations by year
- 2026: 8 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 10 · 2021: 7 · 2020: 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- antidepressant discontinuation, venlafaxine, paroxetine, relapse, long-term outcomes, medication reduction, withdrawal severity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years. https://app.cochat.ai/papers/10.1177/2045125320954609
- The paper
- Groot, P. C., & van Os, J. (2020). Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320954609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.